NFE2L2 and myeloid sarcoma: As dimethyl fumarate has been shown to be a Nrf2 activator in preclinical disease models, we sought to provide human evidence that modulating this target in patients taking dimethyl fumarate for MS might reduce the incidence of chronic diseases where Nrf2 activity has been implicated.